Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache

NCT ID: NCT02423408

Last Updated: 2017-04-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 165 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2016-02-29

Brief Summary

This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of a single dose of TNX-201 (140 mg) for the treatment of a single qualifying Tension-Type-Headache (TTH).

Detailed Description

The study will be conducted in 4 periods (the Screening Period, the Run-In Period, the Double-Blind Treatment Period and the Follow-up Period) and 4 visits (the Screening Visit, Enrollment Visit, Randomization Visit and End-of-Study Visit).

Screening Period- Eligible subjects who provide written informed consent to participate will have study assessments performed at the Screening.

Run-In Period- The Run-In Period will last for at least 28 days. During the Run-In period, subjects will be assessed for frequency of headache, study compliance and to ensure they meet all required study criteria for randomization.

Double-Blind Treatment Period- The Double-Blind Treatment Period (Treatment Period) will last up to 4 weeks or until a qualifying headache episode has occurred and been treated using the study drug, whichever occurs first.

Follow-up Period- All subjects will return to the investigational site for this visit, regardless of whether they have treated a qualifying TTH with study medication. Subjects who have not treated a qualifying TTH with study drug during the Treatment Period will be asked to return study materials and undergo safety evaluations at the End-of-Study Visit and will be discharged from the study. Subjects who have treated a qualifying TTH with study drug during the Treatment Period will ingest a 140 mg dose of open-label TNX-201 at this visit and undergo urine and blood sample collection for 3 hours post-dose to characterize each subject's genetic metabolism and PK profile.

Conditions

Tension-Type Headache

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

TNX-201

4 X 35 mg capsules to be taken when qualifying tension-type headache occurs

Group Type: EXPERIMENTAL

TNX-201

Intervention Type: DRUG

TNX-201 capsule

Placebo

4 X placebo capsules to be taken when qualifying tension-type headache occurs

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo capsule

Interventions

TNX-201

TNX-201 capsule

Intervention Type: DRUG

Placebo

Placebo capsule

Intervention Type: DRUG

Other Intervention Names

(R)-isometheptene mucate; TNX-201 Placebo

Eligibility Criteria

Inclusion Criteria

1. Capable of reading and understanding English and able to provide written informed consent to participate.

2. Male or female adults ≥ 18 and < 65 years of age at the time of Visit 1.

3. Body mass index (BMI) ≥ 18.5 and ≤ 45.0.

4. Greater than 1 year history of episodic tension-type headache with onset prior to 50 years of age.

5. History of tension-type headaches that typically last ≥ 4 hours if untreated.

6. History of 2-14 tension-type headaches per month for the last 3 months prior to Visit 1.

7. Diagnosis must comply with the International Headache Society (IHS) diagnostic criteria.

8. No significant ECG findings at Screening

9. If female, is either not of childbearing potential or is practicing a predefined medically acceptable method of birth control (hormonal methods, intrauterine device, double-barrier method, sexually-exclusive vasectomized male partner, same-sex relationship) throughout the study.

10. Willing and able to comply with all protocol-specified requirements.

Exclusion Criteria

1. Known or suspected hypersensitivity to isometheptene mucate or any excipients used in the formulation.

2. Use of any excluded concomitant medications.

3. Current use of opiate analgesics.

4. Use of any prophylactic drug therapy for headache control within 4 weeks of screening (e.g., anticonvulsants, mood stabilizers, beta-blocker, antidepressants, muscle relaxants, botulinum toxin). Subjects taking any of these medications for an indication other than headache (e.g., a beta-blocker for hypertension) will require medical monitor's approval prior to initiation of the Run-In Period.

5. History of medication use for acute headache on ≥ 10 days per month on average during the 3 months prior to Visit 1.

6. Positive results for addictive substances (e.g., cocaine, phencyclidine (PCP), amphetamines, opiates) at Screening.

7. History of migraine that exceeds a mean of four attacks per month during the preceding calendar year.

8. Lifetime history of schizophrenia, schizoaffective disorder, bipolar I/II disorder, delusional disorder, or psychotic disorder not otherwise specified.

9. Chronic pain disorders requiring medical treatment with opioids, chronic daily use of NSAIDs at the time of screening

10. History of coronary artery disease, coronary vasospasm, aortic aneurysm, peripheral vascular disease or other ischemic diseases (e.g., ischemic bowel syndrome or Raynaud's syndrome).

11. Inadequately controlled hypertension or persistently elevated systolic blood pressure or diastolic blood pressure upon repeat assessment at screening or on the day of randomization.

12. Current history of two or more CAD risk factors at Screening (tobacco use, receiving anti-hypertensive medication for hypertension, high LDL cholesterol or low HDL cholesterol levels, family history of premature CAD, diabetes mellitus)

13. History cerebral vascular accident, transient ischemic attack, seizure disorders.

14. Other clinically significant cardiac disease.

15. History of concurrent illness that requires hospitalization within 30 days prior to Visit 1.

16. Current evidence of human immunodeficiency virus infection or clinically significant hepatitis B or C infection.

17. Clinically significant laboratory abnormalities based on screening laboratory tests and/or medical history.

18. Participation in another investigational trial during the 30 days prior to Visit 1 or during this trial. Subjects who have participated in non-interventional trials may be permitted to participate on a case-by-case basis after review with the Medical Monitor.

19. Women who are pregnant, breast-feeding, or planning to become pregnant during this trial.

20. Any other household member currently participating in a Tonix-sponsored study or family member or relative of investigative staff.

21. Any condition and/or medical history that would make the subject unsuitable for study participation and completion.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tonix Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tracie Ruther, M.S

Role: STUDY_DIRECTOR

1 513 579 9911 ext 2214

Locations

James D. Wolfe, MD

San Jose, California, United States

Avail Clinical Research LLC.

DeLand, Florida, United States

Nathan Segall, MD, CPI

Stockbridge, Georgia, United States

Michigan Head-Pain Neurological Institute

Ann Arbor, Michigan, United States

Gary D. Berman, MD

Minneapolis, Minnesota, United States

John Rubino, MD

Raleigh, North Carolina, United States

PMG Research of Winston-Salem, LLC.

Winston-Salem, North Carolina, United States

Rapid Medical Research, Inc.

Cleveland, Ohio, United States

Stephan C. Sharp, MD

Nashville, Tennessee, United States

Duane G. Wombolt, MD

Norfolk, Virginia, United States

Countries

United States

Other Identifiers

TNX-IS-T201

Identifier Type: -

Identifier Source: org_study_id